Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380841 | 0.83 | KMT2A (0.46) | MEN1KMT2AHSD17B10 | |
| SCHEMBL7588663 | 0.76 | PPARG (0.37) | CYP1A2 | |
| SCHEMBL3263726 | 0.75 | TSHR (0.42) | L3MBTL1GLAMAPTKDM4ECYP1A2 | |
| SCHEMBL28363069 | 0.75 | GABRR1 (0.37) | THRBL3MBTL1GLAGABRR1MAPT | |
| SCHEMBL5111772 | 0.74 | CYP4F2 (0.48) | L3MBTL1MAPTKDM4ECYP1A2HSD17B10 | |
| SCHEMBL25409861 | 0.74 | GABRR1 (0.39) | THRBL3MBTL1GLAGABRR1MAPT | |
| Bromide SCHEMBL28900329 | 0.74 | GABRR1 (0.36) | THRBL3MBTL1GLAGABRR1MAPT | |
| Hydrochloric Acid SCHEMBL28363070 | 0.74 | GABRR1 (0.36) | THRBL3MBTL1GLAGABRR1MAPT | |
| SCHEMBL951011 | 0.73 | KDM4E (0.43) | L3MBTL1MAPTKDM4ECYP1A2MEN1 | |
| SCHEMBL17611676 | 0.72 | AKR1B1 (0.42) | THRBL3MBTL1GLAGABRR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | THRB 512/4885L3MBTL1 1040/4885GLA 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.